|Bid||82.60 x 400|
|Ask||83.00 x 200|
|Day's Range||82.23 - 83.41|
|52 Week Range||63.76 - 86.27|
|PE Ratio (TTM)||8.97|
|Dividend & Yield||2.08 (2.53%)|
|1y Target Est||N/A|
Clinical trial results and FDA meetings expected in the near term could set these stocks up for big gains over the long run.
Gilead Sciences has expanded beyond its leading antiviral drug franchises for the treatment of HIV and hepatitis C with the announced acquisition of Kite Pharmaceuticals, giving Gilead a leading edge in cell therapy technology in oncology.
Gilead Sciences Inc NASDAQ/NGS:GILD